The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B‐cell lymphoma and enhances T‐cell recruitment

An inhibitor of the histone methyltransferase enhancer of zeste homologue 2 (EZH2), tazemetostat, has been developed for the treatment of B‐cell lymphoma, but its mechanisms of action are not fully elucidated. We screened for genes targeted by tazemetostat in eleven B‐cell lymphoma cell lines and fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Hepei, Nishikori, Momoko, Otsuka, Yasuyuki, Arima, Hiroshi, Kitawaki, Toshio, Takaori‐Kondo, Akifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586691/
https://www.ncbi.nlm.nih.gov/pubmed/34449935
http://dx.doi.org/10.1111/cas.15122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586691/
https://www.ncbi.nlm.nih.gov/pubmed/34449935
http://dx.doi.org/10.1111/cas.15122

Ejemplares similares